Yusuke Miyazaki

Universal Brain is on a mission to transform mental health care. By utilizing neuroscience and objective measures, neurotypes can be developed for depression and other mental health conditions, leading to better patient understanding, diagnosis and treatment. At Universal Brain, were innovating EEG wearables to be more accessible and building digital diagnostics and new treatment options for mental health conditions, starting with depression.

Cosomil, Inc. is an innovative start-up dedicated to advancing early cancer detection through the development of blood-based tests. Our groundbreaking technology, known as Single Enzyme Activity-based Protein Profiling, enables ultra-sensitive detection of enzyme activity at the single molecule level using state-of-the-art fluorescent probes and microdevices. コウソミル株式会社は、蛍光プローブとマイクロデバイスを用いて血液中の酵素の活性を1分子レベルの超高感度で検出する独自の「1分子計測リキッドバイオプシー」技術を用いて、癌等の早期疾患診断法の研究開発を行なうスタートアップ企業です。

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

We are driving the evolution of next-generation CAR-T cell therapy with precision-engineered CAR constructs. Our CAR discovery engine focuses on optimizing the binding domain of CAR to enhance immune cell function, delivering robust therapeutic efficacy. Optieum is pushing the boundaries of solid tumor treatment powered by next-generation CAR constructs.

アキュリスファーマ株式会社（英語名：Aculys Pharma, Inc.）は “Catalyst to Access”（革新的な医療への橋渡しを担う）という理念から創られたAculysを社名とする日本発のバイオベンチャー企業です。神経・精神疾患領域において革新的な医療手段への橋渡し役となり、患者さんとご家族、医療関係者、社会により良い医療を届けるため、欧米諸国から革新的で優れた医薬品を導入し、開発・販売を担いさらに疾患を取り巻く様々な課題に対するソリューションを提供します。 Beyond the development and commercialization of new medicines, Aculys is committed to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease. The company looks to form comprehensive solutions through cross-sectional partnerships using new technologies to enhance the patient experience.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.

xFOREST Therapeutics is a Kyoto-based young biotech company. At xFOREST, we develop a proprietary screening pipeline to find RNA-targeting small molecules with the goal to develop them into new drugs that treat previously untreatable diseases. Our pipeline includes both a highly automated laboratory system of liquid- and labware-handling devices and an automated analysis pipeline capable of statistically analyzing millions of potential RNA-small molecule interactions flagging promising hit-pairs. Our vision is to become a next-generation discovery platform that utilizes synergies between wet and dry lab, based on big data and AI.

Strand was founded by biological engineers working together at the Massachusetts Institute of Technology (MIT). Building on the idea of creating smart therapies capable of making sophisticated decisions, they sought to apply this concept to the emerging field of mRNA therapeutics. This area was previously untapped by traditional synthetic biology, leading us to build our very own mRNA programming language, creating the world’s first platform for mRNA smart therapies. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body via mRNA-encoded logic circuits. These circuits have the ability to implement cell-type specific expressions by sensing and classifying the unique mRNA expression signatures of cells and control the dosage of protein expression through responses to exogenously administered small molecules.

株式会社ナレッジパレット

Viage Therapeutics, a neuroscience company based on a platform of novel neurotherapeutics, was founded in 2018. The company is based on the ground-breaking research of Dr. Kousaku Ohinata from Kyoto University. DGX-001, Viage’s clinical drug candidate, represents a first-in-class oral drug candidate targeting the gut-brain axis. The proposed mechanism of action of DGX-001 is to modulate the vagus nerve through specific receptor interactions on enteroendocrine cells in the gut, resulting in a regulation of brain cell activity. DGX-001 is in clinical development and was well-tolerated in a healthy volunteer Phase 1 study, consistent with its positive safety profile in preclinical GLP studies. In the clinical study, DGX-001 increased specific brain activity (EEG measures) and a post hoc analysis indicated improvements in cognition based on Cogstate tests. Furthermore, human PK measurements have so far been undetectable systemically, confirming the preclinical finding the drug candidate is gut-restricted and gut-acting, which may further minimize off-target side effects as majority of PD patients suffer from comorbidities and polypharmacy. Viage plans to initiate the Phase 2 program of DGX-001, which initially aims to achieve cognitive improvement across different diseases, representing a transdiagnostic study design, which may ultimately enable indications beyond neurology and psychiatry. Viage’s pipeline is comprised of both novel neuropeptides and 2nd generation DGX-001-derived peptides and small molecules. It includes SAR-optimized drug candidates with potential in cognitive impairment, depression, anxiety, and inflammatory disease. The drug candidates are gut-acting and gut-restricted, which suggests an advantageous safety profile, particularly compared to most approved psychiatric drugs which suffer from numerous side effects. The Company is headquartered in the San Francisco Bay Area.

Universal Brain is on a mission to transform mental health care. By utilizing neuroscience and objective measures, neurotypes can be developed for depression and other mental health conditions, leading to better patient understanding, diagnosis and treatment. At Universal Brain, were innovating EEG wearables to be more accessible and building digital diagnostics and new treatment options for mental health conditions, starting with depression.

Cosomil, Inc. is an innovative start-up dedicated to advancing early cancer detection through the development of blood-based tests. Our groundbreaking technology, known as Single Enzyme Activity-based Protein Profiling, enables ultra-sensitive detection of enzyme activity at the single molecule level using state-of-the-art fluorescent probes and microdevices. コウソミル株式会社は、蛍光プローブとマイクロデバイスを用いて血液中の酵素の活性を1分子レベルの超高感度で検出する独自の「1分子計測リキッドバイオプシー」技術を用いて、癌等の早期疾患診断法の研究開発を行なうスタートアップ企業です。

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

We are driving the evolution of next-generation CAR-T cell therapy with precision-engineered CAR constructs. Our CAR discovery engine focuses on optimizing the binding domain of CAR to enhance immune cell function, delivering robust therapeutic efficacy. Optieum is pushing the boundaries of solid tumor treatment powered by next-generation CAR constructs.